Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Wang, Yu ^a   Ye, Jiantao ^a,b   Li, Jie ^a   Chen, Cheng ^a   Huang, Junying ^a   Liu, Peiqing ^a,b   Huang, Heqing ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b National and Local United Engineering Lab of Druggability and New Drugs Evaluation   (China)

Author keywords

Dislipidemia; GCK; Hyperglycemia; Insulin resistance; LDLR; PCSK9

Indexed keywords

GCK PROTEIN; PALMITIC ACID; PHOSPHOTRANSFERASE; PICEID; PIOGLITAZONE; PROPROTEIN CONVERTASE SUBTILIN KEXIN TYPE 9; PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GERMINAL CENTER KINASES; GLUCOSE BLOOD LEVEL; GLUCOSIDE; HERBACEOUS AGENT; LDLR PROTEIN, HUMAN; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; SERINE PROTEINASE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; LIPID METABOLISM; LIVER; LIVER PROTECTION; MOLECULAR DOCKING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GLUCOSE BLOOD LEVEL; HEP-G2 CELL LINE; INSULIN RESISTANCE; LIVER CELL; METABOLISM; PROTEIN CONFORMATION; RNA INTERFERENCE; TIME FACTOR;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FEMALE; GLUCOSIDES; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYDROGEN BONDING; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; PALMITIC ACID; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, LDL; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; STILBENES; TIME FACTORS; TRANSFECTION;

EID: 84957964955     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0325-x     Document Type: Article

References (54)

1. Kalsi DS, Chopra J, Sood A. Association of lipid profile test values, type-2 diabetes mellitus, and periodontitis. Indian J Dent. 2015;6(2):81-4. doi: 10.4103/0975-962X.157270.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
3. Aschner PJ, Ruiz AJ. Metabolic memory for vascular disease in diabetes. Diabetes Technol Ther. 2012;14(Suppl 1):S68-74. doi: 10.1089/dia.2012.0012(1557-8593 (Electronic)).
4. Rr H, Sk P, Ma B, Dr M, Ha N. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
5. Schiele F, Park J, Redemann N, Luippold G, Nar H. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J Mol Biol. 2014;426:843-52. doi: 10.1016/j.jmb.2013.11.011.
6. Carri B, Wen S, Zigouras S, Browne RW, Li Z, Patel MS, et al. Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS One. 2014;9(3):e90863. doi: 10.1371/journal.pone.0090863.
7. Zhang Y, Eigenbrot C, Zhou L, Shia S, Li W, Quan C, et al. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem. 2014;289(2):942-55. doi: 10.1074/jbc.M113.514067.
8. Kuhnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103-12. doi: 10.1194/jlr.M051326.
9. Schroeder C, Swedberg JE, Withka JM, Rosengren KJ, Akcan M, et al. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro. Chem Biol. 2014;21:284-94. doi: 10.1016/j.chembiol.2013.11.014.
10. Marais AD, Kim JB, Wasserman SM, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2015;145:58-66. doi: 10.1016/j.pharmthera.2014.07.004.
11. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995-3005. doi: 10.1172/JCI29383DS1.
12. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602-12. doi: 10.1074/jbc.M702027200.
13. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008;49(6):1303-11. doi: 10.1194/jlr.M800027-JLR200.
14. Mbikay M, Sirois F, Mayne J, Wang G-S, Chen A, Dewpura T, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010;584:701-6. doi: 10.1016/j.febslet.2009.12.018.
15. Cariou B, Langhi C, Le Bras M, Bortolotti M, Le KA, Theytaz F, et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond). 2013;10(1):4. doi: 10.1186/1743-7075-10-4.
16. Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009;55(9):1637-45. doi: 10.1373/clinchem.2009.126987.
17. Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: the CODAM study. Atherosclerosis. 2011;217(1):263-7. doi: 10.1016/j.atherosclerosis.2011.03.023.
18. Ai D, Chen C, Han S, Ganda A, Murphy AJ, Haeusler R, et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest. 2012;122(4):1262-70. doi: 10.1172/JCI61919.
19. Sg L, Ta L, Jc C, Jd H, Hh H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537-43.
20. Xie X, Peng J, Huang K, Huang J, Shen X, Liu P, et al. Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-κB signaling pathway in rat glomerular mesangial cells. Mol Cell Endocrinol. 2012;362(1-2):183-93. doi: 10.1016/j.mce.2012.06.008.
21. Zhang J, Tan Y, Yao F, Zhang Q. Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-aα and SREBP-1c. Mol Med Rep. 2012;6(4):815-20. doi: 10.3892/mmr.2012.1015.
22. Li T, Liu Y, Li G, Wang X, Zeng Z, Cai S, et al. Polydatin attenuates ipopolysaccharide-induced acute lung injury in rats. Int J Clin Exp Pathol. 2014;7(12):8401-10 (D - NLM: PMC4314025 OTO - NOTNLM).
23. Shiyu S, Zhiyu L, Mao Y, Lin B, Lijia W, Tianbao Z, et al. Polydatin up-regulates Clara cell secretory protein to suppress phospholipase A2 of lung induced by LPS in vivo and in vitro. BMC Cell Biol. 2011;12((1471-2121 (Electronic))):31. doi: 10.1186/1471-2121-12-31.
24. Li XH, Gong X, Zhang L, Jiang R, Li HZ, Wu MJ, et al. Protective effects of polydatin on septic lung injury in mice via upregulation of HO-1. Mediat Inflamm. 2013;2013(354087):354087. doi: 10.1155/2013/354087.
25. Huang K, Chen C, Hao J, Huang J, Wang S, Liu P, et al. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-beta1 in rat glomerular messangial cells. Mol Cell Endocrinol. 2015;399:178-89. doi: 10.1016/j.mce.2014.08.014.
26. Yang B, Li J-J, Cao J-J, Yang C-B, Liu J, Ji Q-M, et al. Polydatin attenuated food allergy via store-operated calcium channels in mast cell. World J Gastroenterol. 2013;19(25):3980-9. doi: 10.3748/wjg.v19.i25.3980.
27. Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J, Fan S. Polydatin inhibits growth of lung cancer cells by inducing apoptosis and causing cell cycle arrest. Oncol Lett. 2014;7(1):295-301. doi: 10.3892/ol.2013.1696.
28. Du J, Sun LN, Xing WW, Huang BK, Jia M, Wu JZ, et al. Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine. 2009;16(6-7):652-8. doi: 10.1016/j.phymed.2008.10.001.
29. Xing WW, Wu JZ, Jia M, Du J, Zhang H, Qin LP. Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed Pharmacother. 2009;63(7):457-62. doi: 10.1016/j.biopha.2008.06.035.
30. Miao Q, Shi XP, Ye MX, Zhang J, Miao S, Wang SW, et al. Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms. Int J Mol Sci. 2012;13(6):7776-87. doi: 10.3390/ijms13067776.
31. Wu Y, Xue L, Du W, Huang B, Tang C, Liu C, et al. Polydatin restores endothelium-dependent relaxation in rat aorta rings impaired by high glucose: a Novel insight into the PPARβ-NO signaling pathway. PLoS One. 2015;10(5):e0126249. doi: 10.1371/journal.pone.0126249.
32. Hao J, Chen C, Huang K, Huang J, Li J, Liu P, et al. Polydatin improves glucose and lipid metabolism in experimental diabetes through activating the Akt signaling pathway. Eur J Pharmacol. 2014;745:152-65. doi: 10.1016/j.ejphar.2014.09.047.
33. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology. 2006;147(7):3398-407. doi: 10.1210/en.2005-1494.
34. Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y. Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J Biol Chem. 2013;288(30):21861-75. doi: 10.1074/jbc.M113.461905.
35. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis. 2014;235(2):449-62. doi: 10.1016/j.atherosclerosis.2014.05.931.
36. Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem. 2003;46(4):499-511. doi: 10.1021/jm.020406h.
37. Ravagnan G, De Filippis A, Carteni M, De Maria S, Cozza V, Petrazzuolo M, et al. Polydatin, a natural precursor of resveratrol, induces beta-defensin production and reduces inflammatory response. Inflammation. 2013;36(1):26-34. doi: 10.1007/s10753-012-9516-8.
38. Wang HL, Gao JP, Han YL, Xu X, Wu R, Gao Y, et al. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine. 2015;22(5):553-9. doi: 10.1016/j.phymed.2015.03.014.
39. Andrade JMO, Paraíso AF, de Oliveira MVM, Martins AME, Neto JF, Guimarães ALS, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;30(7-8):915-9. doi: 10.1016/j.nut.2013.11.016.
40. Du RH, Dai T, Cao WJ, Lu M, Ding J-H, Hu G. Kir6.2-containing ATP-sensitive K(+) channel is required for cardioprotection of resveratrol in mice. Cardiovasc Diabetol. 2014;13(35):2-9. doi: 10.1186/1475-2840-13-35.
41. Zhang L, Li Y, Gu Z, Wang Y, Shi M, Ji Y, et al. Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-κB signaling pathway. PLoS One. 2015;10(2):e0116879. doi: 10.1371/journal.pone.0116879.
42. Anil TM, Harish C, Lakshmi MN, Harsha K, Onkaramurthy M, Sathish Kumar V, et al. CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models. Cardiovasc Diabetol. 2014;13:27. doi: 10.1186/1475-2840-13-27.
43. Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med. 2012;85(1):19-28 D-NLM: PMC3313535 OTO-NOTNLM.
44. Dentin R, Pegorier JP, Benhamed F, Foufelle F, Ferre P, Fauveau V, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004;279(19):20314-26. doi: 10.1074/jbc.M312475200.
45. Xie X, Li WY, Lan T, Liu WH, Peng J, Huang KP, et al. Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway. Endocrine Journal. 2011;58(9):761-8.
46. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA. 2004;101(18):7100-5. doi: 10.1073/pnas.0402133101.
47. Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284(42):28856-64. doi: 10.1074/jbc.M109.037085.
48. Mbikay M, Sirois F, Simoes S, Mayne J, Chretien M. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio. 2014;4:755-62. doi: 10.1016/j.fob.2014.08.003.
49. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008;283(46):31791-801. doi: 10.1074/jbc.M805971200.
50. Tai MH, Chen PK, Chen PY, Wu MJ, Ho CT, Yen JH. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res. 2014;58(11):2133-45. doi: 10.1002/mnfr.201400366.
51. Giesbertz P, Padberg I, Rein D, Ecker J, Hofle AS, Spanier B, et al. Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes. Diabetologia. 2015;58(9):2133-43. doi: 10.1007/s00125-015-3656-y.
52. Orland MJ, Permutt MA. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes. 1987;36(3):341-7 (Epub 1987/03/01).
53. Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem. 2008;54(6):1038-45. doi: 10.1373/clinchem.2007.099747.
54. Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010;212(1):246-51. doi: 10.1016/j.atherosclerosis.2010.05.027.